FY26 Appendix 4E
Open PDF
| Stock | Cogstate Ltd (CGS.ASX) |
|---|---|
| Release Time | 18 Aug 2026, 8:12 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Cogstate Ltd FY26 Results: Revenue and Profit Growth
Key Points
- Total revenue increased by 14.6% to $60.9m
- Clinical Trials revenue increased by 15.4% to $58.4m
- Profit before tax increased by 15.9% to $16.1m
- Fully franked final dividend of A$0.04 per share declared
Full Summary
Cogstate Ltd reported a strong financial performance for the year ended 30 June 2026, with total revenue from ordinary activities increasing by 14.6% to $60.86 million. Clinical Trials revenue, which accounts for the majority of the company's revenue, saw a significant 15.4% increase to $58.4 million. The company also reported a 15.9% increase in profit before income tax to $16.1 million. The company declared a fully franked final dividend of A$0.04 per share, totaling A$6.8 million.
Guidance
FY26 revenue: $60.86 million, profit before tax: $16.1 million, dividend: A$0.04 per share
Outlook
Cogstate Ltd anticipates continued growth in clinical trials revenue and overall profitability in the coming years.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In